Live Chat ×
Skip to main content

Genomic Studies of Solid Tumors

From the 2019 Joint Annual Meeting (June 26, 2019)
Presented by Daynna Wolff, Ph.D.
Solid tumors exhibit many genomic alterations, both germline and somatic, including single nucleotide variants (SNVs), copy number alterations (CNAs), and structural aberrations. Identification of genomic alterations is important for diagnosis, prognosis, and/or therapy. This presentation will overview genomics testing methods that can be used for clinical assessment, the advantages/limitations of current methods, and emerging concepts in cancer genomics including the significance of premalignant clonal changes, as well as the use of circulating cell-free DNA to assist with cancer screening.

LEARNING OBJECTIVES
At the conclusion of this presentation, participants will be able to:

  1. Describe how whole genome copy number assessment is used for clinical testing
  2. Discuss the utility of integrating copy number data and sequence data to best understand the genomic landscape of tumors
  3. Describe the limits of current genomic technologies and discuss the future of genomic testing for solid tumors

CE ACCREDITATION
This recorded presentation is P.A.C.E. ® accredited. The instruction level for this activity is Intermediate. One (1) P.A.C.E. ® contact hour and one (1) Florida credit hour in the area General (Cytogenetics) will be awarded to participants. ASCLS P.A.C.E.® is accepted by the ASCP/ASCLS/AGT Board of Certification and all states, including Florida and California, as an approved provider of continuing education for recertification and licensure. ASCLS is an approved provider with CE Broker for Florida licensees.

LEVEL OF INSTRUCTION
This intermediate-level program is appropriate for laboratory professionals working in clinical, public health and academic settings.